Progress in the development of small molecules as new human A3 adenosine receptor ligands based on the 3-thiophenylcoumarin core

MedChemComm
2016.0

Abstract

Adenosine receptors (AR) are GPCRs involved in several biochemical processes. Agents able to selectively modulate the activity of theses receptors represent promising multifunctional agents to delay or slow the progression of a large range of diseases. Here, differently substituted 3-thiophenylcoumarins are described that exert affinity towards human AR subtypes. Among the compounds synthesized, the 3-(4-bromothiophenyl) derivative 11 showed the highest affinity and selectivity for the hA3 AR (Ki = 740 nM). Interestingly, the current study revealed that small structural changes in this scaffold allow modulating the AR affinity, suggesting that this scaffold has desirable properties for the development of promising classes of hA1, hA2A, and/or hA3 ARs ligands. Further docking calculations in the hA3 AR identified the hypothetical binding mode for the most active and selective compounds. In addition, theoretical evaluation of some physicochemical properties highlighted the potential of these compounds as drug candidates. The data so far acquired is the first step for further optimization of these 3-thiophenylcoumarins as hA3 AR selective ligands.

Knowledge Graph

Similar Paper

Progress in the development of small molecules as new human A<sub>3</sub> adenosine receptor ligands based on the 3-thiophenylcoumarin core
MedChemComm 2016.0
Structure-Based Optimization of Coumarin hA<sub>3</sub> Adenosine Receptor Antagonists
Journal of Medicinal Chemistry 2020.0
4-Amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as New Potent and Selective Human A<sub>3</sub>Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation, and Ligand−Receptor Modeling Studies
Journal of Medicinal Chemistry 2006.0
2-Amino-3-aroyl-4,5-alkylthiophenes:  Agonist Allosteric Enhancers at Human A<sub>1</sub> Adenosine Receptors
Journal of Medicinal Chemistry 2002.0
Substituted 4-phenylthiazoles: Development of potent and selective A1, A3 and dual A1/A3 adenosine receptor antagonists
European Journal of Medicinal Chemistry 2020.0
Discovery of Novel Adenosine Receptor Agonists That Exhibit Subtype Selectivity
Journal of Medicinal Chemistry 2016.0
New 2-Arylpyrazolo[3,4-c]quinoline Derivatives as Potent and Selective Human A<sub>3</sub>Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation, and Ligand−Receptor Modeling Studies
Journal of Medicinal Chemistry 2007.0
Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a New Scaffold To Develop Potent and Selective Human A<sub>3</sub>Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation, and Ligand−Receptor Modeling Studies
Journal of Medicinal Chemistry 2009.0
1,2,4-Triazolo[1,5-a]quinoxaline as a Versatile Tool for the Design of Selective Human A<sub>3</sub>Adenosine Receptor Antagonists:  Synthesis, Biological Evaluation, and Molecular Modeling Studies of 2-(Hetero)aryl- and 2-Carboxy-Substitued Derivatives
Journal of Medicinal Chemistry 2005.0
N<sup>6</sup>,5‘-Disubstituted Adenosine Derivatives as Partial Agonists for the Human Adenosine A<sub>3</sub> Receptor
Journal of Medicinal Chemistry 1999.0